Proprietary TechnologyNanexa's proprietary NEX-20 platform offers a competitive advantage in drug delivery, potentially enhancing efficacy and safety, which can attract partnerships and drive long-term growth.

Low LeverageA low debt-to-equity ratio suggests financial stability and reduced risk, providing the company with flexibility to invest in growth opportunities without significant financial strain.

Partnership Revenue ModelNanexa's revenue model, based on partnerships and collaborations, allows for diversified income streams and potential for steady cash flow from licensing and royalties.

Bears Say

Negative Cash FlowPersistent negative cash flow indicates ongoing cash burn, which can limit the company's ability to invest in growth and may necessitate additional financing, impacting long-term sustainability.

Revenue ContractionSignificant revenue contraction highlights challenges in market penetration and product adoption, which could hinder long-term growth prospects and profitability.

Negative ProfitabilityOngoing operational losses and negative profitability metrics reflect challenges in achieving sustainable growth and may impact the company's ability to attract investment and finance operations.

Nanexa AB News

Nanexa AB’s Phase 1 Study on NEX-22A: A Potential Game-Changer for Diabetes Treatment?

Nanexa AB (($DE:40M)) announced an update on their ongoing clinical study. Study Overview: The recent clinical study by...

5M ago

40M

40M FAQ

What was Nanexa AB’s price range in the past 12 months?

Nanexa AB lowest stock price was €0.07 and its highest was €0.43 in the past 12 months.

What is Nanexa AB’s market cap?

Nanexa AB’s market cap is €53.19M.

When is Nanexa AB’s upcoming earnings report date?

Nanexa AB’s upcoming earnings report date is Feb 19, 2026 which is today.

How were Nanexa AB’s earnings last quarter?

Currently, no data Available

Is Nanexa AB overvalued?

According to Wall Street analysts Nanexa AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nanexa AB pay dividends?

Nanexa AB does not currently pay dividends.

What is Nanexa AB’s EPS estimate?

Nanexa AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nanexa AB have?

Nanexa AB has 158,676,150 shares outstanding.

What happened to Nanexa AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nanexa AB?

Currently, no hedge funds are holding shares in DE:40M

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nanexa AB

Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.